ArticleCancer reports (Hoboken, N.J.)2025
Chemotherapy-Induced Peripheral Polyneuropathy in Pediatric Acute Lymphoblastic Leukemia: A Case Report on Manifestation, Management, and Outcome.
Article in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChemotherapy-induced peripheral polyneuropathy (CIPN) is a debilitating side effect of cancer treatment such as in acute lymphoblastic leukemia (ALL). Characterized by the dysfunction of the peripheral nervous system, CIPN can occur in 90% of pediatric patients, significantly impairing their quality of life. In most cases, it necessitates the modification of standard chemotherapy regimens, which can compromise the treatment efficacy and increase the risk of relapse. CASE: We report a 16-year-old boy with ALL who developed CIPN during induction therapy. A multidisciplinary, individualized treatment approach combined with regular follow-ups ensured optimal management. The patient achieved complete remission with significant improvement in mobility and neurological functions.
conclusionsEarly recognition and comprehensive management of CIPN in pediatric ALL patients are essential to optimizing outcomes while maintaining the overall efficacy of chemotherapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.